Literature DB >> 9074545

Optimization of technetium-99m-labeled PEG liposomes to image focal infection: effects of particle size and circulation time.

O C Boerman1, W J Oyen, L van Bloois, E B Koenders, J W van der Meer, F H Corstens, G Storm.   

Abstract

UNLABELLED: In previous studies we have shown that liposomes sterically stabilized with polyethylene glycol (PEG), preferentially localize in infectious and inflammatory foci. In this study, we further optimized the formulation of PEG liposomes for infection imaging in a rat model.
METHODS: The biodistribution and imaging characteristics of different liposomal formulations labeled with 99mTc were determined in rats with S. aureus infection of the left calf muscle. The influence of liposomal size (mean diameter varying from 90 nm to 220 nm) as well as circulation time (modulated by inclusion of 0-10 mole% phosphatidylserine) were studied.
RESULTS: The smallest liposomes displayed improved characteristics for infection imaging: 90-nm liposomes revealed the highest abscess uptake (1.6% +/- 0.4% ID/g, 24 hr postinjection) in combination with the lowest splenic accumulation (6.9% +/- 0.7% ID/g, 24 hr postinjection) as compared to the larger sized preparations. Enhanced abscess-to-blood ratios (4.0 versus 1.3 at 24 hr postinjection) were obtained by including 1.0 mole% phosphatidylserine in the lipid bilayer of the PEG liposomes. However, enhanced blood clearance of these liposomes reduced their absolute abscess uptake.
CONCLUSION: These results indicate that the in vivo behavior of PEG liposomes can be modulated to optimize their characteristics for infection imaging.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9074545

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.

Authors:  Mohanambe Lingappa; Hong Song; Sarah Thompson; Frank Bruchertseifer; Alfred Morgenstern; George Sgouros
Journal:  Cancer Res       Date:  2010-07-22       Impact factor: 12.701

2.  1H NMR quantification of poly(ethylene glycol)-phosphatidylethanolamine in phospholipid mixtures.

Authors:  E A Vernooij; C A Gentry; J N Herron; D J Crommelin; J J Kettenes-van den Bosch
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

Review 3.  Nanoparticle approaches against bacterial infections.

Authors:  Weiwei Gao; Soracha Thamphiwatana; Pavimol Angsantikul; Liangfang Zhang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-07-15

4.  WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma.

Authors:  Santiago Saavedra-Alonso; Pablo Zapata-Benavides; Ana Karina Chavez-Escamilla; Edgar Manilla-Muñoz; Diana Elisa Zamora-Avila; Moisés Armides Franco-Molina; Cristina Rodriguez-Padilla
Journal:  Exp Ther Med       Date:  2016-10-27       Impact factor: 2.447

5.  Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.

Authors:  Thais Alves da Costa-Silva; Andrés Jimenez Galisteo; José Angelo Lauletta Lindoso; Leandro R S Barbosa; Andre Gustavo Tempone
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

6.  Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.

Authors:  Cristiano C P Dos Santos; Guilherme S Ramos; Renata C De Paula; Karen F Faria; Paulo O L Moreira; Ramon A Pereira; Maria N Melo; Wagner L Tafuri; Cynthia Demicheli; Raul R Ribeiro; Erly G Azevedo; Rubens Do Monte-Neto; Sydnei M Da Silva; Frédéric Frézard
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

7.  99mTc-radiolabeled Levofloxacin and micelles as infection and inflammation imaging agents.

Authors:  Mine Silindir-Gunay; Asuman Yekta Ozer
Journal:  J Drug Deliv Sci Technol       Date:  2020-02-08       Impact factor: 3.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.